Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 5, 2009, Pages 1671-1677

  Tatsuno, Ichiro ^a,b   Sugiyama, Takao ^a,c   Suzuki, Sawako ^a,b   Yoshida, Tomohiko ^a,b   Tanaka, Tomoaki ^a,b   Sueishi, Makoto ^a,c   Saito, Yasushi ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c SHIMOSHIZU HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; PREDNISOLONE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CLINICAL FEATURE; COLLAGEN DISEASE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; VASCULAR DISEASE; VERTEBRA FRACTURE; ADOLESCENT; AGE; AGED; COHORT ANALYSIS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RISK FACTOR; SEX DIFFERENCE; SPINE; SPINE INJURY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; COHORT STUDIES; COLLAGEN DISEASES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK FACTORS; SEX FACTORS; SPINAL INJURIES; SPINE; VASCULAR DISEASES; YOUNG ADULT;

EID: 66149089530     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1578     Document Type: Article

References (36)

1. Cushing H 1932 The basophilic adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1:137-192
2. Canalis E, Bilezikian JP, Angeli A, Giustina A 2004 Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593-598 (Pubitemid 38393793)
3. Canalis E, Mazziotti G, Giustina A, Bilezikian JP 2007 Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328 (Pubitemid 47389469)
4. Manelli F, Giustina A 2000 Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 11:79-85 (Pubitemid 30164202)
5. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A 2006 Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 17:144-149
6. Shaker JL, Lukert BP 2005 Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am 34:341-356, viii-ix
7. van Staa TP 2006 The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79:129-137
8. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C 2000 Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000 (Pubitemid 30350061)
9. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC, Aydintug AO, Chwalinska-Sadowska H, de Ramon E, Fernandez-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR 2003 Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299-308 (Pubitemid 37229465)
10. Jardinet D, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA 2000 Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford) 39:389-392 (Pubitemid 30307324)
11. Langford CA 1997 Chronic immunosuppressive therapy for systemic vasculitis. Curr Opin Rheumatol 9:41-47 (Pubitemid 27217768)
12. Nagai S, Izumi T 1997 Immunopathology of collagen vascular disease. Curr Opin Pulm Med 3:356-360 (Pubitemid 127498381)
13. Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S, Manzi S 1999 Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 42:882-890 (Pubitemid 29214998)
14. Sinigaglia L, Varenna M, Girasole G, Bianchi G 2006 Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 32:631-658
15. Yee CS, Crabtree N, Skan J, Amft N, Bowman S, Situnayake D, Gordon C 2005 Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 64:111-113 (Pubitemid 40075285)
16. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton IL, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey EV, Mellstrom D 2004 A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893-899 (Pubitemid 41103445)
17. van Staa TP, Leufkens HG, Cooper C 2002 The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787 (Pubitemid 36336722)
18. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148 (Pubitemid 23261108)
19. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN 2000 Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 160:2917-2922 (Pubitemid 32009048)
20. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R 1995 Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 54:801-806
21. Michel BA, Bloch DA, Wolfe F, Fries JF 1993 Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 20:1666-1669 (Pubitemid 24017566)
22. Adachi JD, Ioannidis G, Pickard L, Berger C, Prior JC, Joseph L, Hanley DA, Olszynski WP, Murray TM, Anastassiades T, Hopman W, Brown JP, Kirkland S, Joyce C, Papaioannou A, Poliquin S, Tenenhouse A, Papadimitropoulos EA 2003 The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 14:895-904 (Pubitemid 38009529)
23. De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA 1998 Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 13:1587-1593 (Pubitemid 28465299)
24. Johansson C, Black D, Johnell O, Oden A, Mellstrom D 1998 Bone mineral density is a predictor of survival. Calcif Tissue Int 63:190-196 (Pubitemid 28387969)
25. Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA 1994 Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 4:277-282 (Pubitemid 24291436)
26. Melton 3rd LJ, Crowson CS, O'Fallon WM, Wahner HW, Riggs BL 2003 Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 18:312-318
27. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ 1996 The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010-1018 (Pubitemid 26200053)
28. Chatham WW, Kimberly RP 2001 Treatment of lupus with corticosteroids. Lupus 10:140-147 (Pubitemid 32410067)
29. Parker BJ, Bruce IN 2007 High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 16:387-393 (Pubitemid 47122211)
30. Tatsuno I, Suzuki S, Yoshida T, Tanaka T, Sueishi M, Sugiyama T 2009 High prevalence and early complication of symptomatic vertebral fracture in the elderly treated with high-dose glucocorticoids. J Am Geriatr Soc 57:188-189
31. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R 2007 Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028-2039 (Pubitemid 350106710)
32. Villareal DT 2002 Effects of dehydroepiandrosterone on bone mineral density: what implications for therapy? Treat Endocrinol 1:349-357
33. Khosla S, Amin S, Orwoll E 2008 Osteoporosis in men. Endocr Rev 29:441-464
34. Lips P 2006 Vitamin D physiology. Prog Biophys Mol Biol 92:4-8 (Pubitemid 43831956)
35. Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, Giorgino R, MoroL, Giustina A 2006 High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253-259 (Pubitemid 43870263)
36. de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW 2006 Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355:675-684 (Pubitemid 44244538)